The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The effectively therapeutic approaches for Heart failure with preserved ejection fraction
(HFpEF) remain limited. The PARAGON-HF trial found that Angiotensin Receptor-Neprilysin
Inhibition (ARNI) has potential benefits for the management of HFpEF. Nevertheless, the role
of ARNI in cardiac fibrosis in HFpEF are still unclear. We will conduct a prospective
randomized controlled trial to evaluate the effect of ARNI on cardiac fibrosis in patients
with HFpEF by cardiac magnetic resonance (CMR).